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Abstract
Background: Smad4 is the common mediator of the tumor suppressive functions of TGF-beta. Smad6 and Smad7
are the antagonists of the TGF-beta pathway. This study investigates the differential protein expressions of Smad4,
Smad6 and Smad7 in tumor as compared to normal tissue of pancreatic ductal adenocarcinoma (PDAC) and
compares them with clinicopathological parameters and patient survival.
Results: There was a significant difference in protein expressions of Smad4 (p = 0.0001), Smad6 (p = 0.0015) and
Smad7 (p = 0.0005) protein in tumor as compared to paired normal samples. Loss of Smad7 expression correlated
significantly with tumor size (r = 0.421, p < 0.036) and margin status (r = 0.431; p < .032). Patients with moderate
to high Smad4 protein expression had a better survival (median survival = 14.600 ± 2.112 months) than patients
with absent or weak Smad4 protein expression (median survival = 7.150 ± 0.662). In addition, advanced disease
stage correlated significantly with poor prognosis.
Conclusion: Loss of Smad4 significantly correlated with poor survival of PDAC patients. In the cases where Smad4
is expressed, Smad6 inhibition is possibly a novel mechanism for Smad4 inactivation. Smad7 has a role in
pathobiology of PDAC. Further investigation in the roles of Smad6 and Smad7 would help in the identification of
novel therapeutic targets for PDAC.
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Background
Smad proteins are a family of intracellular mediators of
the transforming growth factor beta (TGF-b) family of
cytokines. On ligand binding, TGF-b Receptor II
(TbRII) becomes constitutively active, heterodimerizes
with TGF-b Receptor I (TbRI) and transphosphorylates
its GS domain resulting in its activation [1,2]. Once acti-
vated, TbRI phosphorylates a class of molecules known
as receptor-regulated Smads (R-Smads), Smad2 and
Smad3, at an SSXS motif at their C-terminal end [3].
Active, phosphorylated R-Smads heterodimerize with
common-Smad (Co-Smad), Smad4, translocate to the
nucleus and regulate gene expression [4,5]. A third class
of Smad proteins, the inhibitory Smads (I-Smads),
Smad6 and Smad7 act as negative regulators and act by
blocking R-Smads’ interaction with TbRI, phosphoryla-
tion by TbRI or heterodimerization with Smad4 [6,7].
Smad4 is being explored as one of the major molecu-
lar markers in pancreatic ductal adenocarcinoma
(PDAC) (as reviewed by [8]). Although lost in many
cancers, loss of Smad4 is more sensitive and specific to
pancreatic cancer [9]. Studies have shown SMAD4 gene
to be inactivated in 55% of pancreatic cancers [10-12].
The inactivation of SMAD4 gene occurs either by
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any medium, provided the original work is properly cited.deletion of both alleles (35%) or by intra-genic mutation
in one allele coupled with the loss of the other allele
(20%) [13]. A number of studies demonstrate the role of
Smad4 in pancreatic ductal adenocarcinoma, but only a
few studies have explored the roles of inhibitory Smads,
Smad6 and Smad7 in this disease (as reviewed by [14]).
In the present study, we examined the differential pro-
tein expressions of Smad4, Smad6 and Smad7 in surgi-
cally resected samples of paired tumor tissue of
pancreatic ductal adenocarcinoma versus adjacent nor-
mal tissue. A combinatorial expression of these three
Smads was evaluated to gain an insight into how they
influenced one another in pancreatic ductal adenocarci-
noma as compared to normal pancreas. Influence of the
expression levels of these proteins on clinicopathological
parameters and patient survival was studied.
Methods
Patients
The study was conducted after obtaining a formal
approval from the Ethics Committee of the Postgraduate
Institute of Medical Education and Research. Informed
oral consent was obtained from each patient for partici-
pation in the study.
Twenty-five prospective cases of histopathologically
proven pancreatic ductal adenocarcinoma, collected over
a period of 36 months at the Department of General Sur-
gery, Postgraduate Institute of Medical Education and
Research, Chandigarh, India, were included in our study.
Out of these 25 subjects, 13 were males and 12 were
females. The mean age of the patients was 54.6 years,
with two patients below 40 and one as young as 28. Fol-
low-up data was collected for all patients. Most PDAC
tumor samples were either highly differentiated (13) or
moderately differentiated (11), with just one case poorly
differentiated. The patients were staged according to the
Tumor, Node and Metastasis (TNM) classification of the
International Union against Cancer [15]. Clinicopatholo-
gical and outcome data is summarized in Table 1.
Tissue Sample
Surgically resected samples were collected and tumor
was confirmed by performing hematoxylin and eosin
(H&E) staining on frozen sections taken on autoclaved
glass slides. Similarly, the presence of normal pathology
in the adjacent normal tissues was also confirmed. Initi-
ally, samples from a total of 32 consecutive patients
were collected, out of which 25 samples that showed
tumor tissue in more than 90% of the area of the section
were included for study. Part of the samples to be used
for immunohistochemistry were formalin fixed, and part
of them were snap frozen and stored at - 80°C for
further molecular analysis.
Clinicopathological Data
Clinical and pathological data were obtained from the
patients’ medical records. Clinical and pathological vari-
ables included age, gender, tumor size, margin status,
stage, grade, and survival.
Immunohistochemistry
Immunohistochemical labeling was done on 4 μmt i s -
sue sections mounted on slides coated with poly-L-
lysine (Sigma, St. Louis, Missouri, USA) using the rou-
tine streptavidin - biotin immunoperoxidase technique.
Sections were deparaffinised in xylene, rehydrated
through a series of graded alcohol to distilled water
and microwaved in buffered sodium citrate. Endogen-
ous peroxidase was blocked by incubating in hydrogen
peroxidase with methanol followed by overnight incu-
bation with monoclonal antibodies, anti-Smad4 (clone
B-8), anti-Smad6 (clone H-150) and anti-Smad7 (clone
H-79), obtained from Santa Cruz Biotechnology Inc.,
Santa Cruz, California, USA. Novastatin Universal
Detection kit (Ready to use, Novacastra Laboratories
Ltd., Newcastle, UK) containing biotinylated secondary
antibody was applied and staining was visualised using
3’,3 ’- Diaminobenzidinetetrahydrochloride (Sigma
Chemical Co., St. Louis, USA) solution as the chromo-
gen. The sections were counterstained in Mayer’s hae-
matoxylin, rinsed in water, and mounted in Di-N-
Butyle Phthalate in Xylene. The brown product
obtained was visualized and scored by light micro-
scopy. Antigen retrieval conditions and the antibody
dilutions used are summarized in Table 2.
Table 1 Clinical profile of patients with pancreatic ductal
adenocarcinoma (n = 25)
Clinical variable Groups No. of patients
Age (range 28-75) < 50 5(20%)
≥ 50 20(80%)
Sex Male 13 (52%)
Female 12 (48%)
Stage I 3 (12%)
II 7 (28%)
III 14 (64%)
IV 1 (4%)
Grade Well differentiated 13 (52%)
Moderately/poorly differentiated 12 (48%)
Tumor size < 3 cm 19 (76%)
≥3 cm 6 (24%)
Margin status Positive 3 (12%)
Negative 22 (88%)
Lymph Node status Positive 6 (24%)
Negative 19 (76%)
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Immunohistochemical scoring was done independently
by two senior cytopathologists (BDR and RS) and only
samples with complete concordance in staining and his-
topathology were included in the study. The slides were
scored as follows: 0 (no staining), 1+ (weak staining), 2+
(moderate staining), and 3+ (strong staining), a scoring
system previously described by Hua et al [16]. Paired
adjacent normal tissue samples served as positive con-
trols for each of the cases. There was a complete con-
cordance in all the cases except one, where high and
moderate expression of Smad4 for the same normal tis-
sue sample was respectively reported. Re-evaluation,
however, eliminated the discrepancy.
Statistical Methods
Fisher’s exact test was used to compare Smad4, Smad6
and Smad7 protein expression in normal and tumor tis-
sue. Spearman rank correlation test was used to corre-
late Smad4, Smad6 and Smad7 protein expression in
tumor tissue with clinicopathological parameters.
Kaplan-Meier survival analysis was used to analyse the
influence of Smad4, Smad6 and Smad7 protein expres-
sion in tumor tissue and clinicopathological parameters
on survival. A probability value of less than 0.05 was
considered to be significant.
Results
Immunohistochemical expression of Smad4, Smad6 and
Smad7
Protein levels of all three Smads, Smad4, Smad6 and
Smad7 were evaluated in paired normal pancreatic tis-
sues and tumor samples of pancreatic ductal adenocarci-
noma (Figure 1; Table 3). A comparison of the protein
levels between normal and tumor tissues for each of the
three Smads is shown in Figure 2.
Smad4
Smad4 showed cytoplasmic as well as nuclear staining,
which was both diffuse and focal (Figure 1a, b). Most
normal tissue showed strong to moderate Smad4 immu-
noreactivity (24/25, 96%), whereas most tumor tissue
showed absent (10/25, 40%) or weak (10/25, 40%)
immunoreactivity for Smad4. Strong to moderate
expression was seen only in 20% (5/25) of tumor sam-
ples. The difference in Smad4 protein levels in tumor
tissue as compared to normal pancreatic tissue was
highly significant on Fisher’s exact test (two tailed p
value = 0.0001).
Smad6
The protein immunoreactivity was predominantly cyto-
plasmic (Figure 1c, d). Here also, most of the normal
tissues showed strong (18/25, 72%) to moderate (5/25,
20%) immunopositivity. However, A good number (12/
25, 48%) of tumor tissues showed moderate levels of
Smad6 protein expression, in contrast to Smad4 where
Table 2 Antibodies used in the study
Antibody Clone* Antigen retrieval Primary antibody incubation Concentrations used
anti-Smad4 Clone B-8 Pressure cooker for 20 min 2 h at room temperature 2 μg/ml (1:100)
anti-Smad6 Clone H-150 Microwaving:3 Cycles 3 min +1 Cycle 1 min Overnight at 4°C 4 μg/ml (1:50)
anti-Smad7 Clone H-79 Microwaving: 3 Cycles 3 min +1 Cycle 1 min Overnight at 4°C 4 μg/ml (1:50)
*All antibodies were obtained from Santa Cruz Biotechnology Inc., CA., USA.
Figure 1 Immunohistochemistry for Smads in paired tumor
and normal pancreatic tissues. Upper panel shows the normal
pancreatic tissue and the down panel shows the corresponding
tumor tissue. Normal pancreas with strong focal and nuclear
positivity (a. ×100) and tumor negative for Smad4 (b. ×400). Normal
pancreas with strong diffuse cytoplasmic positivity (c. ×100) and
tumor with moderate focal cytoplasmic positivity for Smad6 (d.
×200). Normal pancreas with strong diffuse cytoplasmic positivity (e.
×100) and tumor negative for Smad7 protein (f. ×200). (streptavidin-
biotin immunoperoxidase).
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plete loss of Smad6 expression was seen only in 28%(7/
25) of tumor cases. The difference in Smad6 protein
levels in tumor tissue as compared to normal pancreatic
tissue was highly significant by Fisher’s exact test (p =
0.0015).
Smad7
The immunoreactivity was predominantly cytoplasmic,
although occasional nuclear positivity was obtained in
some normal pancreatic ducts (Figure 1e, f). Similar to
Smad4, normal pancreatic tissue showed moderate to
high levels of Smad7 expression in most of the samples
(18/25, 72%), whereas, more than half of tumor tissue
showed complete loss of protein expression (4/25, 56%),
and another 24%(6/25) of cases showed low expression.
The difference in the expression levels of Smad7 in nor-
mal pancreatic samples as compared to tumor samples
was highly significant by Fisher’s exact test (p = 0.0005).
Co-expression of Smad4 with inhibitory Smads
In tumor samples, out of 15 Smad4 positive cases, 10
showed low and 5 showed moderate Smad4 protein
expression. In four out of these five cases, either or both
Smad6 and Smad7 were moderately co-expressed. Over-
all, out of 15 Smad4 positive cases, 14 cases showed
either Smad6 or Smad7 expression, with almost all cases
except one showing Smad6 expression (Table 4).
Correlation of Smad4, Smad6 and Smad7 protein
expression with clinocopathological parameters
A comparison of various clinicopathological parameters
with Smad4, Smad6 and Smad7 protein expressions
using Spearman correlation was done (Table 5). Absent/
low Smad7 protein expression showed a significant posi-
tive correlation with tumour size (r = 0.421, p < .036)
and margin status (r = 0.431; p < .032).
Univariate analysis for survival
The mean (± SEM) survival of patients was 8.64 ± 4.5
months and the median survival was 9 months. 20% of
patients survived over one year. Kaplan-Meier analysis
for survival demonstrated that patients with moderate to
high Smad4 protein expression had a better survival
(median survival = 14.600 ± 2.112 months) than patients
with absent or weak Smad4 protein expression (median
survival = 7.150 ± 0.662) [Log Rank (Mantel-Cox) Chi
Square 9.116, significance .003] (Figure 3, Table 6). Even
on adjusting individually for the stage, tumor size, grade
and margin status of PDAC tumor samples, moderate to
high Smad4 protein expression positively influences sur-
vival significantly [Log Rank (Mantel-Cox) Chi-Square
8.250, significance .004; Log Rank (Mantel-Cox) Chi-
Square 9.772, significance .002; Log Rank (Mantel-Cox)
Table 3 Immunohistochemical expression of Smad4,
Smad6 & Smad7 in paired samples of Normal pancreas
and Pancreatic ductal adenocarcinoma (n = 25)
IHC Score Smad4 Smad6 Smad7
Normal Tumor Normal Tumor Normal Tumor
0 1(4%) 10(40%) 1(4%) 7(28%) 3(12%) 14(56%)
1+ 0(0%) 10(40%) 1(4%) 6(24%) 4(16%) 6(24%)
2+ 8(32%) 5(20%) 5(20%) 12(48%) 8(32%) 4(16%)
3+ 16(64%) 0(0%) 18(72%) 0(0%) 10(40%) 1(4%)
Figure 2 Frequency of protein expression in normal pancreas
and pancreatic ductal adenocarcinomas for Smad4, Smad6 and
Smad7, respectively. The x-axis represents the
immunohistochemistry score and y-axis represents the number of
cases.
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Cox) Chi-Square 8.524, significance .004]. Smad 6 and
Smad 7 protein expression did not influence survival.
Stage I & II patients showed a longer survival (median
survival 10 ± 2.066 months) as compared to those in
Stage III & IV (median survival 7 ± .949 months) [Log
Rank (Mantel-Cox) Chi-Square 4.644, significance .031]
(Figure 3, Table 6).
Discussion
Smad4 is the common mediator of the tumor suppres-
sive functions of TGF-beta. Smad6 and Smad7 are
antagonists of the TGF-beta pathway. In this work, we
further establish the role of Smad4 as a potential prog-
nostic marker for pancreatic ductal adenocarcinoma.
We also identified different roles for Smad6 and Smad7
in influencing pancreatic cancer biology.
In this study, Smad4 was expressed in most of the
normal samples (96%) but lost in 40% of tumor samples.
In tumor samples, even where it was expressed, there
w a sw e a ke x p r e s s i o ni nt h em a j o r i t yo fc a s e s .K a p l a n -
Meier analysis for survival demonstrated that patients
with moderate Smad4 protein expression had a better
survival than patients with weak or negative Smad4 pro-
tein expression. Despite one report of Smad4 expression
to be inversely related to survival in surgically resected
pancreatic ductal adenocarcinoma patients [17], there is
growing evidence for the correlation of Smad4 status to
patient survival in this disease [16,18]. One study also
correlated the Smad4 expression with the pattern of dis-
ease progression (local v distant dominant) and pro-
posed to further explore its role as a predictive
biomarker for personalized treatment strategies [19].
Our observations further adds to preexisting data and
establish Smad4 as a potential prognostic marker for
pancreatic ductal adenocarcinoma. However, a recent
meta-analysis analyzing 5 studies evaluating Smad4
could not find any significant overall association
between Smad4 expression and survival [20]. This indi-
cates difficulty in making a reliable conclusion regarding
the relative prognostic value of immunohistochemical
markers when analyzed in a limited patient series.
Table 4 Combinatorial expression of Smad4, Smad6 & Smad7 in 25 tumor samples of pancreatic ductal
adenocarcinoma patients
Positive cases
Smad6
(n = 18, 72.0%)
Smad7
(n = 11, 44.0%)
Smad6 or Smad7
(n = 21, 84.05)
Smad6 and Smad7
(n = 9, 36%)
Smad4 positive cases (n = 15) 14 (93.3%) 9 (60.0%) 15 (100%) 5 (55.5%)
Smad4 negative cases (n = 10) 4 (40.0%) 2 (20.0%) 9 (90.0%) 4 (44.5%)
Table 5 Correlations of the expression of Smad4, Smad6 and Smad7 with clinicopathological parameters in 25
patients of pancreatic ductal adenocarcinoma
Parameters Groups No.
(n)
Loss/low expression of
Smad4 (%)
P
value
(2-
tailed)
Loss/low expression of
Smad 6 (%)
P
value
Loss/low expression of
Smad7(%)
P
value
Age < 50 5 4 (16%) 1.000 4 (16%) 0.244 4 (16%) 1.000
≥ 50 20 16 (40%) 10 (40%) 16 (64%)
Sex Male 13 10 (40%) 0.704 7(28%) 0.830 10(40%) 0.704
Female 12 10 (40%) 7 (28%) 10 (40%)
Grade G1 13 11 (44%) 0.567 8 (32%) 0.580 9 (36%) 0.175
G2 12 9 (36%) 6 (24%) 11 (44%)
Stage I+II 10 7 (28%) 0.328 5 (20%) 0.639 8 (32%) 1.000
III+IV 15 13 (52%) 9 (36%) 12 (48%)
LN status Negative 19 15 (60%) 0.824 9 (36%) 0.132 15 (60%) 0.824
Positive 6 5 (20%) 5 (20%) 5(20%)
Tumor size < 3 cm 19 16 (64%) 0.370 11(44%) 0.747 17 (68%) 0.036*
≥3 cm 6 4 (16%) 3 (12%) 3 (12%)
Margin
status
Positive 3 2 (8%) 0.558 1(4%) 0.420 1 (4%) 0.032*
Negative 22 18 (72%) 13 (52%) 19 (76%)
*Significant values
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showed nuclear staining, cytoplasmic staining was pre-
dominant. Previous reports have shown that while
Smad7 appears to reside predominantly in the nucleus
at basal state, it translocates to the cytoplasm upon
TGF-b stimulation [21]. The cytoplasmic staining of
Smad6 and Smad7 in most samples implies that these
two inhibitory Smads were in their activated states in
most tumor samples.
There are just two reports on Smad6 expression in
pancreatic cancer till date. One of them conducted in
pancreatic cancer cell line, found Smad6 and Smad7
levels to be elevated in pancreatic cancer [22]. The sec-
ond study, conducted on patient samples, contradicts
this and demonstrates that the increased expressions of
either Smad6 or Smad7 are infrequent in tumor com-
pared to normal samples [23]. Our study goes a step
further, and shows that Smad6 as well as Smad7 are lost
in tumor as compared to normal samples. We showed a
loss of expression of Smad6 in 28% tumor samples as
compared to 8% loss in normal samples. In cases where
Smad6 was expressed, the expression was mostly mod-
erate to high. Its cytoplasmic staining, along with its co
expression with Smad4 in 14 out of 15 Smad4 positive
cases suggests that Smad6 can be one of the possible
inhibitory mechanisms for Smad4 inactivation. Thus, in
pancreatic ductal adenocarcinoma cases where Smad4
itself is not lost, we illustrate a novel mechanism for its
inhibition. Our study, for the first time ascribes Smad6
a role in pancreatic cancer biology, which can be further
explored for the development of novel therapeutic
target.
Previous studies have shown Smad7 overexpression in
pancreatic cancer cell lines [22-24]. Similar to our study,
few other studies have shown a loss of Smad7 in patient
samples [24,25]. This difference in expression in cell
lines as compared to tissue samples might be because of
a possible reversal of phenotype in artificial tissue cul-
ture systems. In our study, loss of Smad7 expression
surpassed that of Smad4 and was absent in 56% of
tumor samples, which is quite close to what has been
reported by Guo et al [24]. Amongst clinicopathological
parameters, loss of Smad7 significantly correlated with
both tumor size as well as margin status. On similar
lines, Wang et al showed a significant correlation
between the low Smad7 expression and lymph node
metastasis [26]. These observations, put together, indi-
cate a role for Smad7 in the aggressiveness of this dis-
ease. In fact, different studies have isolated different
molecules, like KLF11, retinoblastoma, thioredoxin,
which are involved in Smad7 dependent aggressiveness
of pancreatic cancer [23,27,28]. However, unlike Wang
et al, we did not find a significant correlation between
loss of Smad7 and patient survival.
The smaller sample size in the study is acknowledged,
the reasons being i) choice of prospective samples for
the study, ii) low incidence of pancreatic cancer in
Indian population: 0.5-2.4 per 100000 men and 0.2-1.8
Figure 3 Kaplan-Meier plot for disease specific survival:
according to Smad4 protein expression (a.) and according to
Stage of pancreatic ductal adenocarcinoma (early: I + II;
advanced: III + IV) (b.).
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tion of patient samples, iv) exclusion of archival samples
due to poor and unreliable staining.
Conclusions
T h ep r e s e n ts t u d ys t r o n g l ys u b s t a n t i a t e st h ep r e v i o u s
reports in further establishing the role of Smad4 as a
prognostic marker. It also suggests that a further
exploration into the newly found roles for Smad6 and
Smad7 in PDAC biology, with a larger sample size, may
help discern some novel therapeutic targets for this dis-
ease, subsequently contributing to the improvement in
therapeutic strategies and better disease management
for PDAC patients.
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